Preventative Treatments / the Role of the HPV Vaccine

  • Gardasil (HPV4)

In the summer of 2006, the FDA approved the use of the first HPV vaccine, Gardasil (HPV4, Merck & Co.). The recombinant, quadrivalent vaccine was intended for the prophylactic treatment of girls and young women 9 though 26 years of age for the prevention of the following pathologies caused by HPV types 16 and 18: cervical, vulvar, and vaginal cancer, and condyloma acuminata.

In addition, HPV4 is indicated for the prevention of precancerous or dysplastic lesions caused by HPV 6, 11, 16, and 18 Gardasil triggers the formation of host antibodies to the HPV subtypes, which are directly responsible for approximately 90 percent of genital warts and 70 percent of cervical cancers. Gardasil injections are administered in three separate doses and appear to be 99-percent effective in preventing genital wart formation in patients naïve to HPV infection.

Read more..

Leave a Comment

Your email address will not be published.